Portal de Periódicos da CAPES

Dupilumab for moderate–severe atopic dermatitis: a real‐world, single‐center retrospective study of 122 patients in the United States

2023; Wiley; Volume: 63; Issue: 4 Linguagem: Inglês

10.1111/ijd.16973

1365-4632

Veronica K. Emmerich, Josiah Williams, Matthew L. Hrin, Steven R. Feldman, Lindsay C. Strowd,

Asthma and respiratory diseases

International Journal of DermatologyEarly View Clinical Correspondence Dupilumab for moderate–severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States Veronica K. Emmerich MD, Veronica K. Emmerich MD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorJosiah A. Williams MD, Josiah A. Williams MD orcid.org/0000-0002-8304-4249 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorMatthew L. Hrin MD, Corresponding Author Matthew L. Hrin MD [email protected] orcid.org/0000-0002-2769-3156 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorSteven R. Feldman MD, PhD, Steven R. Feldman MD, PhD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Dermatology, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorLindsay C. Strowd MD, Lindsay C. Strowd MD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this author Veronica K. Emmerich MD, Veronica K. Emmerich MD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorJosiah A. Williams MD, Josiah A. Williams MD orcid.org/0000-0002-8304-4249 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorMatthew L. Hrin MD, Corresponding Author Matthew L. Hrin MD [email protected] orcid.org/0000-0002-2769-3156 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorSteven R. Feldman MD, PhD, Steven R. Feldman MD, PhD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Dermatology, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorLindsay C. Strowd MD, Lindsay C. Strowd MD Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this author First published: 13 December 2023 https://doi.org/10.1111/ijd.16973 Reviewed and approved by Wake Forest University Health Sciences IRB00065482. Conflict of interest: Dr. Steven Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, Abbvie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Sanofi, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr. Lindsay Strowd has received research, speaking, and/or consulting support from Galderma, Sanofi, Actelion, and Pfizer. The remaining authors have no conflicts to disclose. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017; 35(3): 327–334. https://doi.org/10.1016/j.det.2017.02.005 10.1016/j.det.2017.02.005 CASPubMedWeb of Science®Google Scholar 2Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019; 181(1): 80–87. https://doi.org/10.1111/bjd.17791 10.1111/bjd.17791 CASPubMedWeb of Science®Google Scholar 3Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020; 21(1): 119–131. https://doi.org/10.1007/s40257-019-00478-y 10.1007/s40257-019-00478-y PubMedWeb of Science®Google Scholar 4Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84(1): 139–147. https://doi.org/10.1016/j.jaad.2020.08.051 10.1016/j.jaad.2020.08.051 CASPubMedWeb of Science®Google Scholar 5Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021; 1(3):100042. https://doi.org/10.1016/j.xjidi.2021.100042 10.1016/j.xjidi.2021.100042 PubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation